TY - JOUR
T1 - Prognostic impact of baseline immunologic profile in aggressive b-cell non-hodgkin's lymphomas
AU - Ramadan, Safaa
AU - Ceparano, Giusy
AU - Cignetti, Alessandro
AU - Sammassimo, Simona
AU - Bagnardi, Vincenzo
AU - Pagan, Eleonora
AU - Gottardi, Daniela
AU - Fiori, Stefano
AU - Passerini, Rita
AU - Radice, Tommaso
AU - Saglio, Giuseppe
AU - Tarella, Corrado
N1 - Funding Information:
Acknowledgments. This work was supported in part by grants for research programs to C.T. by Banca del Piemonte (Torino, Italy) and by Piaggio and C. SpA (Pontedera, Italy).
Publisher Copyright:
© 2021 Universita Cattolica del Sacro Cuore. All rights reserved.
PY - 2021/3/1
Y1 - 2021/3/1
N2 - Host immune homeostasis as an independent prognostic indicator has been inadequately evaluated in aggressive non-Hodgkin's lymphomas (NHL). The present study addresses the prognostic significance in aggressive NHLs of the immunologic profile evaluated by pretreatment serum levels of immunoglobulins (Ig) and lymphocyte-monocyte ratio (LMR). In this series of 90 patients with aggressive lymphoma, the median level for IgG was 1,024mg/dl (range 436-2236), and for LMR was 2.2 (range 0.2-13.8). CR rate was higher with IgG levels ≥1,024mg/dL (91% vs 77% p=0.059). LMR ≤ 2.2 was associated with lower 1-year PFS (73% vs. 92%, p 0.016). Patients with good/very good R-IPI showed a reduced PFS if IgG or LMR was low, while patients with poor R-IPI did better if LMR or IgG levels were high. We combined both parameters with the R-IPI and produced a four-risk prognostic score showing one-year PFS of 95% (95% CI 68%-99%), 100% (95% CI 100%-100%), 73% (95% CI 52%-86%), and 59% (95% CI 31%-79%), in patients with zero, one, two and three risk factors, respectively. The results indicate for the first time the value of baseline serum Ig levels in the prognostic assessment of aggressive lymphoma.
AB - Host immune homeostasis as an independent prognostic indicator has been inadequately evaluated in aggressive non-Hodgkin's lymphomas (NHL). The present study addresses the prognostic significance in aggressive NHLs of the immunologic profile evaluated by pretreatment serum levels of immunoglobulins (Ig) and lymphocyte-monocyte ratio (LMR). In this series of 90 patients with aggressive lymphoma, the median level for IgG was 1,024mg/dl (range 436-2236), and for LMR was 2.2 (range 0.2-13.8). CR rate was higher with IgG levels ≥1,024mg/dL (91% vs 77% p=0.059). LMR ≤ 2.2 was associated with lower 1-year PFS (73% vs. 92%, p 0.016). Patients with good/very good R-IPI showed a reduced PFS if IgG or LMR was low, while patients with poor R-IPI did better if LMR or IgG levels were high. We combined both parameters with the R-IPI and produced a four-risk prognostic score showing one-year PFS of 95% (95% CI 68%-99%), 100% (95% CI 100%-100%), 73% (95% CI 52%-86%), and 59% (95% CI 31%-79%), in patients with zero, one, two and three risk factors, respectively. The results indicate for the first time the value of baseline serum Ig levels in the prognostic assessment of aggressive lymphoma.
KW - Aggressive B-cell non-hodgkin's lymphoma
KW - IGG
KW - Immunologlobulin
KW - Lymphocyte-monocyte ratio
KW - Prognosis
UR - http://www.scopus.com/inward/record.url?scp=85103251935&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85103251935&partnerID=8YFLogxK
U2 - 10.4084/MJHID.2021.018
DO - 10.4084/MJHID.2021.018
M3 - Article
AN - SCOPUS:85103251935
VL - 13
JO - Mediterranean Journal of Hematology and Infectious Diseases
JF - Mediterranean Journal of Hematology and Infectious Diseases
SN - 2035-3006
IS - 1
M1 - e2021018
ER -